| Project/Area Number |
25670441
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Endocrinology
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
KAWANO Mitsuo 三重大学, 医学(系)研究科(研究院), 講師 (00234097)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATO Takuma 三重大学, 大学院医学系研究科, 准教授 (60224515)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | hPIV2 / 乳癌 / 遺伝子免疫療法 / 腫瘍免疫 / 免疫活性化 / 細胞性免疫 / 液性免疫 / 転移 / PIV2 / 生体制御 |
|---|
| Outline of Final Research Achievements |
Recently, we have established a novel functional replication-deficient virus vector; a recombinant human parainfluenza type 2 virus vector (hPIV2): highly safe, expressive and immunogenic vector.
In this study, we have developed hPIV2 engineered to express Ag85B (hPIV2/Ag85B) and investigated antitumor effects against breast cancer metastasis by intranasal administration to a breast cancer like model mice generated by transplanting 4T1-Luc cells using the hPIV2/Ag85B. Especially, suppression effects of breast cancer metastasis were recognized in mouse lungs vaccinated high dose hPIV2/Ag85B.
|
